{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:24:07Z","timestamp":1770481447317,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s00415-009-5039-0","type":"journal-article","created":{"date-parts":[[2009,2,27]],"date-time":"2009-02-27T18:23:10Z","timestamp":1235758990000},"page":"910-915","source":"Crossref","is-referenced-by-count":49,"title":["Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism"],"prefix":"10.1007","volume":"256","author":[{"given":"Michele","family":"Tinazzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Bovi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Pasquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Steinmayr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Moretto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Fiaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Ottaviani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,1]]},"reference":[{"key":"5039_CR1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1212\/01.wnl.0000302255.49113.51","volume":"70","author":"MV Alvarez","year":"2008","unstructured":"Alvarez MV, Evidente VG (2008) Understanding drug-induced parkinsonism: separating pearls from oy-sters. Neurology 70:32\u201334","journal-title":"Neurology"},{"key":"5039_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00429294","volume":"31","author":"B Angrist","year":"1973","unstructured":"Angrist B, Sathananthan G, Gershon S (1973) Behavioural effect of l-dopa in schizophrenic patients. Psychopharmacologia 31:1\u201311","journal-title":"Psychopharmacologia"},{"key":"5039_CR3","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/1531-8257(200007)15:4<692::AID-MDS1014>3.0.CO;2-V","volume":"15","author":"HTS Benamer","year":"2000","unstructured":"Benamer HTS, Patterson J, Wyper D, Hadley DM, Macphee GJA, Grosset DG (2000) Correlation of Parkinson\u2019s disease severity and duration with [123I]FP-CIT SPET striatal uptake. Mov Disord 15:692\u2013698","journal-title":"Mov Disord"},{"key":"5039_CR4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002590000460","volume":"28","author":"J Booij","year":"2001","unstructured":"Booij J, Speelman JD, Hornstinkm M, Wolters EC (2001) The clinical benefit of striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with others forms of parkinsonism. Eur J Nucl Med 28:266\u2013272","journal-title":"Eur J Nucl Med"},{"key":"5039_CR5","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1212\/WNL.52.6.1214","volume":"52","author":"JH Bower","year":"1999","unstructured":"Bower JH, Maraganore DM, McDonnel SK, Rocca WA (1999) Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976\u20131990. Neurology 52:1214\u20131220","journal-title":"Neurology"},{"key":"5039_CR6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1212\/WNL.43.3_Part_1.552","volume":"43","author":"DJ Burn","year":"1993","unstructured":"Burn DJ, Brooks DJ (1993) Nigral dysfunction in drug-induced parkinsonism: an 18 F-dopa PET study. Neurology 43:552\u2013556","journal-title":"Neurology"},{"key":"5039_CR7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1176\/ajp.144.7.934","volume":"144","author":"M Davidson","year":"1987","unstructured":"Davidson M, Keefe RSE, Mohs RC, Siever LJ, Losonczy MF, Horvath TB, Davis KL (1987) l-Dopa challenge and relapse in schizophrenia. Am J Psychiatry 144:934\u2013938","journal-title":"Am J Psychiatry"},{"key":"5039_CR8","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(70)90368-5","volume":"2","author":"P Fleming","year":"1970","unstructured":"Fleming P, Makar H, Hunter KR (1970) Levodopa in drug-induced extrapyramidal disorders. Lancet 2:1186","journal-title":"Lancet"},{"key":"5039_CR9","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jnnp.51.6.850","volume":"51","author":"RJ Hardie","year":"1988","unstructured":"Hardie RJ, Lees AJ (1988) Neuroleptic-induced Parkinson\u2019s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 51:850\u2013854","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5039_CR10","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s007020100006","volume":"108","author":"S Hassin-Baer","year":"2001","unstructured":"Hassin-Baer S, Sirota P, Korczyn AD, Treves TA, Epstein B, Shabtai H, Martin T, Litvinjuk Y, Giladi N (2001) Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm 108:1299\u20131308","journal-title":"J Neural Transm"},{"key":"5039_CR11","first-page":"13","volume":"11","author":"RS Hausner","year":"1983","unstructured":"Hausner RS (1983) Neuropleptic induced parkinsonism and Parkinson\u2019s disease: differential diagnosis and treatment. J Clin Psychiatry 11:13\u201316","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 3","key":"5039_CR12","first-page":"III\/22","volume":"253","author":"G Hirose","year":"2006","unstructured":"Hirose G (2006) Drug induced parkinsonism: a review. J Neurol 253(Suppl 3):III\/22\u2013III\/24","journal-title":"J Neurol"},{"key":"5039_CR13","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.20748","volume":"21","author":"M Lorberboym","year":"2006","unstructured":"Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R (2006) [123I] FP\/CIT SPET imaging for distinguishing drug-induced parkinsonism from Parkinson\u2019s disease. Mov Disord 21:510\u2013514","journal-title":"Mov Disord"},{"key":"5039_CR14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00007611-199005000-00011","volume":"8","author":"LG Miller","year":"1990","unstructured":"Miller LG, Jankovic J (1990) Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J 8:525\u2013532","journal-title":"South Med J"},{"key":"5039_CR15","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1093\/brain\/119.6.2097","volume":"119","author":"PK Morrish","year":"1996","unstructured":"Morrish PK, Sawle GV, Brooks DJ (1996) Regional changes in [18F]dopa metabolism in the striatum in Parkinson\u2019s disease. Brain 119:2097\u20132103","journal-title":"Brain"},{"key":"5039_CR16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10072-006-0718-4","volume":"27","author":"S Ottaviani","year":"2006","unstructured":"Ottaviani S, Tinazzi M, Pasquin I, Nothdurfter W, Tomelleri G, Fincati E, Nordera G, Moretto G, Fiaschi A, Smania N, Girogetti P, Antonini A (2006) Comparative analysis of visual and semi-quantitative assessment of striatal [123I] FP-CIT-SPET binding in Parkinson\u2019s disease. Neurol Sci 27:397\u2013401","journal-title":"Neurol Sci"},{"issue":"Suppl 7","key":"5039_CR17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/mds.10579","volume":"18","author":"W Pirker","year":"2003","unstructured":"Pirker W (2003) Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 18(Suppl 7):43\u201351","journal-title":"Mov Disord"},{"key":"5039_CR18","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/mds.21505","volume":"22","author":"C Scherfler","year":"2007","unstructured":"Scherfler C, Schwarz J, Antonini A, Grosser D, Valldeoriola F, Marek K, Oertel W, Tolosa E, Lees AJ, Poewe W (2007) Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord 22:1229\u20131238","journal-title":"Mov Disord"},{"key":"5039_CR19","doi-asserted-by":"crossref","first-page":"BP30","DOI":"10.1007\/s00259-002-0814-5","volume":"29","author":"K Tatsch","year":"2002","unstructured":"Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Haldin C, Pilowsky LS, Pupi A (2002) European Association of Nuclear Medicine procedure guidelines for brain neurotrasmission SPET using (123)I-labelled dopamine (D2) transporter ligands. Eur J Nucl Med 29:BP30\u2013BP35","journal-title":"Eur J Nucl Med"},{"key":"5039_CR20","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/mds.22098","volume":"23","author":"M Tinazzi","year":"2008","unstructured":"Tinazzi M, Ottaviani S, Isaias IU, Pasquin I, Steimayr M, Vampini C, Pilleri M, Moretto G, Fiaschi A, Smania N, Giorgetti P, Antonimi A (2008) [123I] FP-CIT SPET imaging in drug-induced parkinsonism. Mov Disord 23:1825\u20131829","journal-title":"Mov Disord"},{"issue":"Suppl 7","key":"5039_CR21","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1002\/mds.10575","volume":"18","author":"E Tolosa","year":"2003","unstructured":"Tolosa E, Coelho M, Gallardo M (2003) DAT imaging in drug induced and psychogenic parkinsonism. Mov Disord 18(Suppl 7):S28\u2013S33","journal-title":"Mov Disord"},{"key":"5039_CR22","first-page":"528","volume":"12","author":"JA Yaryura-Tobias","year":"1970","unstructured":"Yaryura-Tobias JA, Wolpert A, Dana L, Merlis S (1970) The action of l-dopa on schizophrenic patients, a preliminary report. Curr Ther Res 12:528\u2013531","journal-title":"Curr Ther Res"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-009-5039-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-009-5039-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-009-5039-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:08:24Z","timestamp":1559056104000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-009-5039-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,1]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["5039"],"URL":"https:\/\/doi.org\/10.1007\/s00415-009-5039-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,1]]}}}